Shire Falls Most Since June on Adderall XR Competition
This article is for subscribers only.
Shire Plc, the world’s largest maker of drugs for attention-deficit hyperactivity disorder, fell the most in almost eight months after its once-best-selling Adderall XR treatment got a new generic competitor.
Shire dropped 5.5 percent to 2,027 pence, the biggest single-day decline since June 25, giving the company a market value of 11.3 billion pounds ($17.5 billion).